Orally active heparin and low-molecular-weight heparin

Current Opinion in Pulmonary Medicine

Volumn 7, Issue 5, 2001, Pages 344-348

  Pineo, Graham F ^a,c   Hull, Russell D ^a   Marder, Victor J ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b JOINT REPLACEMENT INSTITUTE   (United States)

^c FOOTHILLS HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; N [8 (2 HYDROXYBENZOYL)AMINO]CAPRYLATE; UNCLASSIFIED DRUG;

ADULT; ANIMAL MODEL; ARTERY THROMBOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS; VEIN THROMBOSIS;

EID: 0034816352     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200109000-00016     Document Type: Review

References (31)

1. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
2. Low-molecular-weight heparins
3. Non-anti-coagulant uses of heparin
4. Comparison of the oral direct thrombin inhibitor H 376/95 with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: A phase II dose-finding study
5. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients
6. Use of antithrombotic agents during pregnancy
7. Sublingual administration of heparin
8. Absorption of heparin from the intestine
9. An investigation of routes of administration of heparin other than injection
10. Effects of acidity, cations and alcoholic fractionation of absorption of heparin from gastrointestinal tract
11. The observation of heparin on endothelium after injection
12. Determination of absolute amounts of heparin and of dextran sulfate in plasma in microgram quantities
13. Evidence from endothelium of gastric absorption of heparin and of dextran sulfates 8000
14. Antithrombotic activity of oral unfractionated heparin
15. Antithrombotic activity of orally administered low molecular weight heparin (logiparin) in a rat model
16. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis
17. Antithrombotic efficacy in a rat model of the low molecular weight heparin, reviparin sodium, administered by the oral route
18. Clinical use of intrapulmonary heparin
19. Enhancement of jejunal absorption of heparinoid sodium ethylenediamine-tetraacetate in the dog
20. Olive oil-provoked, bile-dependent absorption of heparin from the gastrointestinal tract in rats
21. Intestinal absorption of heparin facilitated by sulphate or sulfonated surfactant
22. Oral administration of low molecular weight heparin fractions in rabbits
23. Low molecular weight heparin-like preparations with oral activity
24. Intraduodenal absorption in the rabbit of a novel heparin solution
25. N-acylated α-amino acids as novel oral delivery agents for proteins
26. 4-[4-(2 Hydroxybenzoyl)amino]phenylbutyric acid as a novel delivery agent for recombinant human growth hormone
27. Heparin absorption across the intestine: Effects of sodium N-(8-(2-hydroxybenzoyl)amino)caprylate in rat in situ intestinal installations and in caco-2 monolayers
28. Oral delivery of heparin in combination with sodium N-(8-(2-hydroxybenzoyl)amino)caprylate: Pharmacology considerations
29. Oral delivery of anticoagulant doses of heparin: A randomized, double blind, controlled study in humans
30. Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis
31. Heparin administered orally via a novel carrier system (SNAC) is comparable to subcutaneous heparin when used to prevent venous thromboembolic events following elective total hip arthroplasty (THA)